Sorafenib (DrugBank: Sorafenib)
2 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 34 | 神経線維腫症 | 2 |
| 86 | 肺動脈性肺高血圧症 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2011-001789-16-GB (EUCTR) | 26/08/2011 | 17/05/2011 | Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas - Sorafenib in NF2 | Investigation of the intra-tumoural concentration and activity of sorafenib in cutaneous schwannomas - Sorafenib in NF2 | Neurofibromatosis, type 2 (acoustic neurofibromatosis) MedDRA version: 14.0;Level: LLT;Classification code 10029271;Term: Neurofibromatosis, type 2 (acoustic neurofibromatosis);System Organ Class: 10010331 - Congenital, familial and genetic disorders | Plymouth Hospital NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 14 | Phase 4 | United Kingdom | |||
| 2 | NCT00727233 (ClinicalTrials.gov) | July 8, 2008 | 31/7/2008 | Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | Neurofibromatosis Type I;Plexiform Neurofibroma | Drug: Nexavar (BAY 43-9006) (Sorafenib);Drug: Toxicity, Pharmacokinetics;Drug: Pharmacodynamics;Drug: Radiographic Evaluation;Drug: QOL assessment, Neuropsychological;Drug: Bony Toxicity | National Cancer Institute (NCI) | NULL | Completed | 3 Years | 18 Years | All | 9 | Phase 1 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000001709 | 2009/02/01 | 16/02/2009 | Multikinase Inhibitor (Tyrosine and Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pulmonary Arterial Hypertension | pulmonary arterial hypertension | administration of sorafenib, which is the multikinase inhibitor (tyrosine and serine/threonine kinase inhibitor) | Medical Education Center, School of Medicine, Keio University | NULL | Pending | 20years-old | Not applicable | Male and Female | 10 | Not selected | Japan | |
| 2 | NCT00452218 (ClinicalTrials.gov) | March 2007 | 26/3/2007 | Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) | Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | Drug: Sorafenib | University of Chicago | Bayer | Completed | 18 Years | N/A | Both | 12 | Phase 1 | United States |